Key result
Timolol inhibits exercise-induced tachycardia with ~8 times the potency of propranolol.
Why the study?
Does timolol have comparable beta-blocking potency and effects on systolic time intervals compared to propranolol in healthy subjects and patients with coronary artery disease?
Does timolol have comparable beta-blocking potency and effects on systolic time intervals compared to propranolol in healthy subjects and patients with coronary artery disease?
Timolol is eight times as potent as propranolol, and both drugs maintain considerable beta-blocking effects at the end of a 12-hour dosing interval, supporting twice-daily administration.
Supports twice-daily dosing considerations for both agents; leaves open comparative outcomes in contemporary CAD populations.
The beta-blocking potency of timolol was compared with that of propranolol under steady-state conditions in eight healthy subjects. The effects on systolic time intervals in healthy subjects and patients (n = 6) with coronary artery disease were evaluated in relation to varying timolol dose schedules and plasma concentrations. The beta-blocking potency was assessed by the inhibition of exercise-induced tachycardia. Timolol was eight times as potent as propranolol. There was wide between-patient variation (2.6 to 13.8) in timolol plasma concentration, and correlation between dose and peak (r = 0.61, p < 0.01) or nadir (r = 0.5 p < 0.01). There was a relatively weak correlation between timolol plasma concentration and degree of beta-blockade (r = 0.45, p < 0.05) and a linear correlation with dose (r = 0.98, p < 0.001). In healthy subjects timolol and propranolol had variable effects on systolic time intervals but in patients with coronary artery disease equipotent doses prolonged the preejection period, isovolumetric contraction time, and the ratio of the preejection period over the left ventricular ejection time. In patients as well as in normal subjects, the data indicated considerable beta-blocking effects for both drugs at the end of a 12-hourly dosing schedule, suggesting that twice-daily timolol and propranolol may be clinically practical.
No takes yet. Share an insight, caveat, or question.
Singh et al. (1980) studied Coronary artery disease (n=14). Timolol vs. Propranolol was evaluated on Beta-blocking potency assessed by the inhibition of exercise-induced tachycardia. Timolol was eight times as potent as propranolol in inhibiting exercise-induced tachycardia, with both drugs showing considerable beta-blocking effects at the end of a 12-hourly dosing schedule.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: